Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/art.34519 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience.
Eur J Haematol
October 2024
Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Letermovir, a novel anti-cytomegalovirus (CMV) agent acts by inhibiting the viral terminase complex and is approved for primary prophylaxis in CMV seropositive patients post allogeneic hematopoietic cell transplantation (HCT). The favorable efficacy and safety profile make it an attractive option for use as secondary prophylaxis in patients at high-risk for CMV reactivation. In this study, we report the efficacy and safety of letermovir secondary prophylaxis after at least one treated episode of CMV reactivation in a cohort of 39 high-risk patients.
View Article and Find Full Text PDFTherapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Antimicrob Agents Chemother
August 2022
Division of Infectious Diseases, University Hospital of Genevagrid.150338.c, Geneva, Switzerland.
Article Synopsis
- Letermovir is used for preventing cytomegalovirus (CMV) in patients who have received hematopoietic stem cell transplants (HSCT), and its therapeutic drug monitoring (TDM) was studied for effectiveness and practicality.
- A study involving 40 adult patients found that letermovir levels in the blood remained stable for 70 days after treatment, but there was significant variability among patients.
- The presence of certain medications, such as posaconazole and cyclosporine, increased letermovir levels, while no clear links were found between these levels and the incidence of breakthrough CMV infections.
Associations of high anti-CMV IgG titer with renal function decline and allograft rejection in kidney transplant patients.
J Chin Med Assoc
February 2022
Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Background: An anti-cytomegalovirus (CMV) immunoglobulin G (IgG) antibody is produced after primary CMV infection and generally persists after the primary infection. However, it is not well-known about the relationship between anti-CMV IgG titer and outcomes in kidney transplant recipients. We, therefore, aimed to explore the role of anti-CMV IgG titer on the risks of CMV disease development, allograft rejection, renal function decline, and mortality.
View Article and Find Full Text PDFAssociation of cytomegalovirus diseases with newly developed myocardial infarction and congestive heart failure: data from a national population-based cohort.
Arch Med Sci
March 2021
Divison of Infectious Disease, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Introduction: Anti-cytomegalovirus (CMV) IgG seropositive and/or titer are associated with a higher risk of cardiovascular diseases (CVD). However, it is not clear whether CMV end-organ disease may have a relation with development of CVD or chronic heart diseases.
Material And Methods: In matched cohort study, the National Health Insurance Database covering 50 million people was used to identify 667 patients with CMV diseases and aged ≥ 20 years between 2010 and 2014.
Impairments in Peripheral Blood T Effector and T Regulatory Lymphocytes in Bipolar Disorder Are Associated with Staging of Illness and Anti-cytomegalovirus IgG Levels.
Mol Neurobiol
January 2021
Department of Psychiatry, Queen's University School of Medicine, 752 King Street West, Postal Bag 603, Kingston, ON, K7L7X3, Canada.
There is now evidence that, based on cytokine profiles, bipolar disorder (BD) is accompanied by simultaneous activation of the immune-inflammatory response system (IRS) and the compensatory immune-regulatory system (CIRS), and that both components may be associated with the staging of illness. Nevertheless, no BD studies have evaluated the IRS/CIRS ratio using CD (cluster of differentiation) molecules expressed by peripheral blood activated T effector (Teff) and T regulatory (Treg) subpopulations. This study examined Teff/Treg subsets both before and after ex vivo anti-CD3/CD28 stimulation using flow cytometric immunophenotyping in 25 symptomatic remitted BD patients and 21 healthy controls and assessed human cytomegalovirus (HCMV)-specific IgG antibodies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!